Introduction
============

In the management of suspected stable angina, women are less likely than men to be referred for cardiac investigations or undergo coronary revascularization.[@ehz903-B1] This is despite a higher prevalence of angina[@ehz903-B2] and a 50% higher lifetime risk of dying from coronary heart disease (CHD).[@ehz903-B3] Differences in clinical presentation in women contribute to under-recognition and less intensive treatment,[@ehz903-B4]^,^[@ehz903-B5] and research studies in CHD may represent women less.[@ehz903-B6]

Patients with stable chest pain are evaluated using anatomical imaging with computed tomography coronary angiography (CTCA) or functional testing including stress electrocardiography, radionuclide scintigraphy, echocardiography, or magnetic resonance imaging.[@ehz903-B7] In the Scottish Computed Tomography of the Heart (SCOT-HEART) trial, we reported that among patients referred for the evaluation of stable chest pain, CTCA clarified the diagnosis and altered subsequent management.[@ehz903-B12] At 5 years, CTCA-guided management added to standard care reduced the rate of death from CHD or non-fatal myocardial infarction (MI).[@ehz903-B13]

We investigated whether treatment and outcomes following CTCA-guided management differ between women and men. We hypothesized that there are sex differences for the diagnosis of CHD, patient management (including investigations and treatment), and clinical outcomes, including CHD death and MI, at 5 years.

Methods
=======

Study population
----------------

The SCOT-HEART study was a prospective clinical trial investigating the role of CTCA in patients aged between 18 and 75 years, referred to a cardiology clinic with suspected angina due to CHD. Patients with a prior history of CHD were eligible to participate. The standard care clinical assessment included exercise electrocardiography. The study design and principal findings[@ehz903-B12]^,^[@ehz903-B13] have been reported previously. The study population was randomized 1:1 to standard care or standard care plus ≥64-slice CTCA using a web-based system. Patients gave written informed consent.

Procedures
----------

Cardiovascular risk was calculated with the ASSIGN score. ASSIGN has been developed, calibrated and validated for use in the UK.[@ehz903-B14]

Obstructive coronary artery disease was defined as a luminal stenosis \>70% in one or more major epicardial vessel, or \>50% stenosis in the left main stem.[@ehz903-B15]

At 6 weeks, attending clinicians were asked to review patients\' diagnosis and management in view of all available information including the CTCA report (standard care plus CTCA) or the ASSIGN score (standard care alone). The clinician documented changes in diagnosis, investigations (stress testing or invasive coronary angiography), or treatments (preventive and antianginal treatments). Anginal symptoms were assessed by a self-administered Seattle Angina Questionnaire[@ehz903-B16] with telephone follow-up for non-responders after two mailings 2 weeks apart.

Outcomes
--------

The primary outcome of the trial was the proportion of patients diagnosed with angina secondary to CHD at 6 weeks. A false-positive or negative baseline diagnosis was determined to have occurred when the treating clinician changed the diagnosis at 6 weeks. Key secondary outcomes included changes in treatment or investigations at 6 weeks; CTCA findings; and changes from baseline in Seattle Angina Questionnaire after 6 weeks and 6 months.[@ehz903-B12] The principal clinical endpoints included the composite of death due to CHD or non-fatal MI and coronary revascularization procedures. These events were identified with data from the Information and Statistics Division of the National Health Service (NHS) Scotland and, when appropriate, confirmed by review of patient health records.[@ehz903-B13]

Statistical analyses
--------------------

We performed a *post hoc* analysis stratified by sex. The analyses were performed according to the intention-to-treat principle. Missing data were removed from the analyses, except for data on deaths, which were censored at the time the patient was lost from the trial.

The diagnoses of CHD and angina due to CHD were assessed for certainty (yes/no vs. unlikely/probable in the primary analysis) and frequency (yes/probable vs. unlikely/no) of diagnoses.

Changes in diagnosis, planned investigations, and medical therapies were analysed within mixed-effects logistic regression models to calculate odds ratio with sex included as an interaction term. We obtained standard errors for absolute risk reduction for each sex assuming that the difference in risk between CTCA and control arm was approximately normal. The standard error for difference in absolute risk reduction between men and women was estimated as the square root of the sum of the standard errors squared for each sex. As some of the numbers were small, we repeated this analysis using simulation (sampling from Beta distributions) obtaining very similar results. Results are reported as odds ratios and absolute risk reductions with 95% confidence intervals (CIs). Clinical endpoint events were analysed with Cox regression models, similarly adjusted, and cumulative event curves were constructed.

All analyses were performed using R software, version 3.5.0 (R Foundation for Statistical Computing). Anonymized data will be made available on request.

Results
=======

Characteristics of the study participants
-----------------------------------------

Between 18 November 2010 and 24 September 2014, 4146 (42%) of 9849 patients who had been referred for assessment of suspected angina at 12 cardiology centres across the UK were enrolled and randomly assigned to standard care or standard care and CTCA.

Of 4146 randomized patients, 1821 (44%) were women (*Table [1](#ehz903-T1){ref-type="table"}* and *Figure [1](#ehz903-F1){ref-type="fig"}*). Demographics and comorbidities were evenly distributed between the randomized groups. Compared to men, women had a lower frequency of prior CHD in the standard care \[49 (5.4%) vs. 137 (11.8%), *P* \< 0.001\] and CTCA-guided groups \[49 (5.4%) vs. 137 (11.8%), *P* \< 0.001\]. Fewer women were classified as having 'typical' chest pain symptoms in the CTCA-guided group \[women: 281 (30.9%) vs. men: 456 (39.2%); *P* \< 0.001\] although no difference was demonstrated within the standard care group \[women: 301 (33.1%) vs. men: 424 (36.5%); *P* = 0.117\]. Women were half as likely to be referred for invasive angiography in both groups \[standard care, women 76 (8.4%) vs. men 184 (15.8%); CTCA, women 59 (6.5%) vs. men 196 (16.9%)\].

![Trial design](ehz903f1){#ehz903-F1}

###### 

Characteristics of the participants prior to randomization according to sex

                                                         Standard care   *P*-value (women vs. men)   Standard care + CTCA   *P*-value (women vs. men)                 
  ------------------------------------------------------ --------------- --------------------------- ---------------------- --------------------------- ------------- ---------
  Number                                                 910             1163                                               911                         1162          
  Demographics                                                                                                                                                        
   Age (years)                                           57.0 (9.2)      56.9 (10.0)                 0.794                  57.5 (9.7)                  56.8 (9.7)    0.121
   Body mass index (kg/m^2^)                             29.9 (6.5)      29.6 (5.6)                  0.229                  30.4 (6.8)                  29.2 (4.8)    \<0.001
   Atrial fibrillation                                   13 (1.4)        28 (2.4)                    0.153                  11 (1.2)                    33 (2.8)      0.016
  Cardiovascular risk factors                                                                                                                                         
   Cigarette smoker[^a^](#tblfn3){ref-type="table-fn"}   458 (50.4)      632 (54.5)                  0.067                  452 (49.7)                  643 (55.4)    0.011
   Hypertension                                          303 (33.6)      380 (33.0)                  0.795                  304 (33.7)                  408 (35.5)    0.428
   Diabetes mellitus                                     83 (9.1)        138 (11.9)                  0.053                  77 (8.5)                    146 (12.6)    0.003
   Hypercholesterolaemia                                 502 (55.2)      679 (58.4)                  0.154                  513 (56.3)                  716 (61.6)    0.017
   Family history                                        432 (47.7)      397 (34.6)                  \<0.001                427 (47.5)                  460 (39.9)    0.001
   History of coronary heart disease                     49 (5.4)        137 (11.8)                  \<0.001                49 (5.4)                    137 (11.8)    \<0.001
  Medications                                                                                                                                                         
   Anti-platelet medication                              401 (44.1)      583 (50.1)                  0.021                  399 (43.8)                  610 (52.5)    \<0.001
   Statin                                                341 (37.5)      543 (46.7)                  \<0.001                338 (37.1)                  564 (48.5)    \<0.001
   Beta-blockade                                         180 (19.8)      304 (26.1)                  0.003                  198 (21.7)                  306 (26.3)    0.029
   ACE-inhibitor/ARB                                     130 (14.3)      214 (18.4)                  0.040                  118 (13.0)                  223 (19.2)    \<0.001
   Calcium channel blocker                               84 (9.2)        110 (9.5)                   0.919                  80 (8.8)                    103 (8.9)     0.527
   Nitrates                                              241 (26.5)      349 (30.0)                  0.193                  219 (24.0)                  351 (30.2)    0.004
   Other antianginal therapy                             31 (3.4)        44 (3.8)                    0.736                  29 (3.2)                    49 (4.2)      0.267
   Anginal symptoms[^b^](#tblfn4){ref-type="table-fn"}                                               0.118                                                            \<0.001
    Typical                                              301 (33.1)      424 (36.5)                                         281 (30.9)                  456 (39.2)    
    Atypical                                             231 (25.4)      255 (22.0)                                         254 (27.9)                  248 (21.3)    
    Non-anginal                                          377 (41.5)      482 (41.5)                                         375 (41.2)                  458 (39.4)    
   Electrocardiogram                                                                                                                                                  
    Normal                                               783 (87.0)      952 (82.7)                  0.009                  789 (88.1)                  968 (84.0)    0.010
  Stress electrocardiogram                                                                           \<0.001                                                          \<0.001
   Performed                                             746 (82.3)      1007 (87.0)                                        756 (83.3)                  1008 (87.1)   
   Normal                                                477 (69.4)      612 (64.4)                                         491 (69.0)                  616 (65.3)    
   Inconclusive                                          129 (18.8)      154 (16.2)                                         139 (19.5)                  146 (15.5)    
   Abnormal^‡^                                           81 (11.8)       185 (19.5)                                         82 (11.5)                   182 (19.3)    
  Further investigations                                                                                                                                              
   Stress imaging                                                                                                                                                     
    Radionuclide                                         129 (14.2)      84 (7.2)                    \<0.001                115 (12.6)                  61 (5.2)      \<0.001
    Other                                                7 (0.8)         6 (0.5)                     0.719                  6 (0.7)                     9 (0.8)       0.504
   Invasive coronary angiography                         76 (8.4)        184 (15.8)                  \<0.001                59 (6.5)                    196 (16.9)    \<0.001
   Baseline diagnosis of angina due to CHD                                                           \<0.001                                                          \<0.001
    No                                                   103 (11.3)      163 (14.0)                                         110 (12.1)                  157 (13.5)    
    Unlikely                                             524 (57.6)      537 (46.3)                                         525 (57.7)                  538 (46.3)    
    Probable                                             239 (26.3)      363 (31.3)                                         240 (26.4)                  362 (31.2)    
    Yes                                                  43 (4.7)        98 (8.4)                                           35 (3.8)                    105 (9.0)     
   Baseline diagnosis of CHD                                                                         \<0.001                                                          \<0.001
    No                                                   49 (5.4)        83 (7.1)                                           58 (6.4)                    80 (6.9)      
    Unlikely                                             487 (53.6)      495 (42.6)                                         475 (52.2)                  477 (41.0)    
    Possible                                             314 (34.5)      420 (36.2)                                         328 (36.0)                  444 (38.2)    
    Yes                                                  59 (6.5)        163 (14.0)                                         49 (5.4)                    161 (13.9)    

Values are expressed as *n* (%) or mean ± standard deviation. Missing data (standard care alone, standard care + CTCA): atrial fibrillation *n* = 4 (3, 1); prior coronary heart disease *n* = 4 (3, 1); smoking habit *n* = 7 (5, 2); hypertension *n* = 41 (20, 21); hypercholesterolaemia *n* = 4 (3, 1); family history *n* = 43 (21, 22); angina symptoms *n* = 4 (3, 1); concomitant therapies *n* = 4 for all (3, 1 for all); resting electrocardiogram *n* = 46 (22, 24); exercise electrocardiogram *n* = 18 (10, 8); exercise electrocardiogram outcome *n* = 234 (121, 113); further investigations *n* = 6 (4, 2); stress imaging *n* = 4 (3, 1); coronary angiography *n* = 4 (3, 1); and baseline diagnosis *n* = 4 (3, 1).

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CHD, coronary heart disease.

Current/ex-smokers.

National Institute for Health and Care Excellence criteria.

Findings on computed tomography coronary angiography
----------------------------------------------------

Of 2073 participants \[*n* = 911 (44%) women\] randomized to CTCA-guided management, 1778 participants underwent CTCA (*Table [2](#ehz903-T2){ref-type="table"}*). Eighty-one percent of women had a low coronary calcium score (\<100 AU), vs. 53% of men (*P* \< 0.001). On CTCA, the proportion of women with normal coronary arteries was two-fold higher than in men, whereas 105 (11.5%) of 911 women had obstructive CHD, which was nearly three-fold lower than in men \[*n* = 347 (29.9%) of 1162, *P* \< 0.001\]. The proportions of men with single-, two-, and three-vessel obstructive CHD were two to five-fold higher than in women (*Table [2](#ehz903-T2){ref-type="table"}* and *[Take home figure](#ehz903-F2){ref-type="fig"}*).

![Women were more likely than men to have (*A*) atypical chest pain and normal coronary arteries leading to (*B*) greater false-positive diagnoses of coronary heart disease and angina due to coronary heart disease. Overall, women had low rates of clinical events (coronary heart disease death or non-fatal myocardial infarction) at 5 years but derived a similar prognostic benefit from computed tomography coronary angiography as men. (*C*) Cumulative event curves for the principal long-term clinical endpoint in those assigned to standard care plus computed tomography coronary angiography (blue) and standard care alone (red) amongst women (solid lines) and men (dashed lines).](ehz903f2){#ehz903-F2}

###### 

Findings disclosed by computed tomography coronary angiography in men and women

                                             Women (*N* = 911)   Men (*N* = 1162)   *P*-value
  ------------------------------------------ ------------------- ------------------ -----------
  Coronary calcium score                     *N* = 787           *N* = 1006         \<0.001
   Low (\<100 AU)                            638 (81.1)          529 (52.6)         
   Medium (100--400 AU)                      94 (11.9)           210 (20.9)         
   High (\>400 AU)                           55 (7.0)            267 (26.5)         
  Computed tomography coronary angiography   *N* = 774           *N* = 997          \<0.001
   Normal                                    384 (49.6)          263 (26.3)         
   Non-obstructive CHD                                                              
    Mild (\<50%)                             172 (22.2)          200 (20.0)         
    Moderate (50--70%)                       113 (14.6)          187 (18.8)         
  Obstructive CHD                                                                   
   One-vessel                                60 (7.8)            147 (14.7)         
   Two-vessel                                31 (4.0)            97 (9.7)           
   Three-vessel                              14 (1.8)            103 (10.3)         

Values are expressed as *n* (%).

AU, Agatston Units; CHD, coronary heart disease.

Baseline and 6-week diagnoses of coronary heart disease and angina due to CHD
-----------------------------------------------------------------------------

Overall, CTCA resulted in more frequent diagnostic changes in women than men (absolute risk difference 5.68, 95% CI: 2.71--8.65, *P*-interaction \< 0.001). Because standard care-guided management also resulted in more frequent changes in the diagnosis of CHD amongst women than men, the relative benefits of CTCA were similar \[relative risk 14.6, 95% CI 8.6--27.5 (women) vs. 16.9, 95% CI 9.2--35.6 (men), *Table [3](#ehz903-T3){ref-type="table"}*\]. However, there were important differences in the direction of this change in diagnosis. CTCA-guided management was more likely to identify a false-positive baseline CHD diagnosis amongst women \[103 of 377 (27.3%) (CTCA) vs. 9 of 373 (2.4%) (standard care), number needed to scan 4.0, 95% CI 3.4--5.0\] compared with men \[41 of 605 (6.8%) (CTCA) vs. 5 of 583 (0.9%) (standard care), number needed to scan 16.9, 95% CI 12.4--26.7\] ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}*, *[Take home figure](#ehz903-F2){ref-type="fig"}*). Conversely, the proportion of false-negative baseline diagnoses was similar for women \[72 of 533 (13.5%) (CTCA) vs. 3 of 536 (0.5%) (standard care), number needed to scan 7.7, 95% CI 6.3--10.0\] compared with men \[111 of 557 (19.9%) (CTCA) vs. 3 of 578 (0.5%) (standard care), number needed to scan 5.2, 95% CI 4.4--6.3\].

###### 

Change in diagnosis of coronary heart disease and angina

  ------------------------------------------ ------------------- ------------------- -------------------
  Change in diagnosis of CHD                                                         
   Standard care, *N* (%)                    No change           Change              
    Female                                   898                 12                  
    Male                                     1154                9                   
   CTCA, *N* (%)                                                                     
    Female                                   736                 175                 
    Male                                     1010                152                 
                                             Female              Male                Interaction
   Odds ratio                                17.8 (10.3--34.0)   19.3 (10.4--41.0)   1.1 (*P* = 0.860)
   Absolute risk change                      17.9%               12.3%               *P* \< 0.001
   Difference in absolute risk               5.7 (2.7--8.7)                          
  Change in diagnosis of angina due to CHD                                           
   Standard care, *N* (%)                    No change           Change              
    Female                                   900                 10                  
    Male                                     1154                9                   
   CTCA, *N* (%)                                                                     
    Female                                   774                 137                 
    Male                                     1057                105                 
                                             Female              Male                Interaction
   Odds ratio                                15.9 (8.8--32.6)    12.7 (6.8--27.2)    0.8 (*P* = 0.642)
   Absolute risk change                      13.9%               8.3%                *P* \< 0.001
   Difference in absolute risk               5.6 (2.2--8.8)                          
  ------------------------------------------ ------------------- ------------------- -------------------

Similarly, regarding the classification of angina due to CHD, CTCA changed the diagnosis in 54 (7.8%) of 694 men and 45 (7.1%) of 634 women thought not to have CHD and excluded the diagnosis in 51 (10.9%) of 467 men and 92 (33.7%) of 273 women (*[Take home figure](#ehz903-F2){ref-type="fig"}*). As before, CTCA changed the diagnosis of angina due to CHD more frequently in women compared with men (absolute risk difference 5.66, 95% 2.72--8.65, *P*-interaction = 0.007).

Changes in investigations and treatment at 6 weeks
--------------------------------------------------

There were no differences in invasive coronary angiography or coronary revascularization rates between standard care and CTCA-guided care. CTCA-guided management resulted in cancellation of tests (myocardial perfusion imaging and stress echocardiography) with an absolute risk difference of 4.45 (95% CI: 2.25--6.65); *P* \< 0.001) and changes in antianginal therapy \[absolute risk difference: 4.5 (95% CI: 1.9--7.2), *P* \< 0.001\]. CTCA-guided management resulted in similar rates of changes to preventative therapy (*Table [4](#ehz903-T4){ref-type="table"}*).

###### 

Changes in investigations and treatments at 6 weeks

  ---------------------------------------- ------------------- ------------------- -------------
  Preventative medications---change                                                
   Standard care, *N* (%)                  No change           Change              
    Female                                 872                 38                  
    Male                                   1111                52                  
   CTCA, *N* (%)                                                                   
    Female                                 749                 162                 
    Male                                   955                 207                 
                                           Female              Male                Interaction
   Odds ratio                              5.0 (3.5--7.3)      4.6 (3.4--6.4)      *P* = 0.779
   Absolute risk change                    13.6%               13.3%               
   Difference in absolute risk reduction   0.3 (−3.5 to 4.0)   *P* = 0.890         
  Antianginal medications---change                                                 
   Standard care, *N* (%)                  No change           Change              
    Female                                 902                 8                   
    Male                                   1155                8                   
   CTCA, *N* (%)                                                                   
    Female                                 802                 109                 
    Male                                   1078                84                  
                                           Female              Male                Interaction
   Odds ratio                              15.3 (7.9--34.4)    11.2 (5.8--25.3)    *P* = 0.556
   Absolute risk change                    11.1%               6.5%                
   Difference in absolute risk reduction   4.5 (1.9--7.2)      *P* \< 0.001        
  Stress imaging investigations---change                                           
   Standard care, *N* (%)                  No change           Change              
    Female                                 906                 4                   
    Male                                   1161                2                   
   CTCA, *N* (%)                                                                   
    Female                                 832                 79                  
    Male                                   1116                46                  
                                           Female              Male                Interaction
   Odds ratio                              21.5 (8.9--70.7)    23.9 (7.4--146.8)   *P* = 0.904
   Relative risk                           19.7 (7.3--53.6)    23.9 (5.8--98.8)    
   Absolute risk change                    8.2%                3.8%                
   Difference in absolute risk reduction   4.5 (2.3--6.7)      *P* \< 0.001        
  ---------------------------------------- ------------------- ------------------- -------------

CTCA, computed tomography coronary angiography.

Angina
------

There were no sex differences in physical limitation, angina stability, frequency, satisfaction with treatment, and quality of life, as assessed using the Seattle Angina Questionnaire, at 6 weeks and 6 months, when compared with baseline observations (*Table [1](#ehz903-T1){ref-type="table"}*).

Clinical endpoints
------------------

After a median of 4.8-year follow-up, women had a lower composite endpoint rate of death due to CHD or MI or death due to CHD, MI, or stroke than men (*[Take home figure](#ehz903-F2){ref-type="fig"}*). Crude differences in health outcomes and adjusted hazard ratios were observed between women and men for CTCA-guided management vs. standard care (*Table [5](#ehz903-T5){ref-type="table"}*).

###### 

Clinical outcomes by sex and treatment group after a median of 4.8 years

                                              Standard care vs. CTCA   Interaction *P*-value[^a^](#tblfn9){ref-type="table-fn"}                                                                      
  ------------------------------------------- ------------------------ ---------------------------------------------------------- -------------------- ------------ ------------ ------------------- -------
  CHD death or myocardial infarction          11 (1.2)                 22 (2.4)                                                   0.50 (0.24--1.04)    37 (3.2)     59 (5.1)     0.63 (0.42--0.95)   0.572
  CHD death myocardial infarction or stroke   19 (2.1)                 26 (2.9)                                                   0.72 (0.40--1.30)    44 (3.8)     71 (6.1)     0.63 (0.43--0.91)   0.686
  Cardiovascular events                                                                                                                                                                              
   Myocardial infarction                      11 (1.2)                 21 (2.3)                                                   0.53 (0.25--1.10)    33 (2.8)     52 (4.5)     0.64 (0.41--0.99)   0.638
   Stroke                                     8 (0.9)                  5 (0.5)                                                    1.57 (0.50--4.89)    7 (0.6)      15 (1.3)     0.47 (0.19--1.15)   0.099
  Death                                                                                                                                                                                              
   CHD                                        0 (0.0)                  1 (0.1)                                                    ---                  4 (0.3)      8 (0.7)      0.51 (0.15--1.71)   ---
   Cardiovascular                             1 (0.1)                  1 (0.1)                                                    1.42 (0.08--24.38)   4 (0.3)      11 (0.9)     0.38 (0.12--1.20)   0.532
   Non-cardiovascular                         12 (1.3)                 8 (0.9)                                                    1.45 (0.59--3.56)    26 (2.2)     23 (2.0)     1.17 (0.67--2.06)   0.701
   All-cause                                  13 (1.4)                 9 (1.0)                                                    1.42 (0.60--3.33)    30 (2.6)     34 (2.9)     0.92 (0.56--1.50)   0.403
  Procedures                                                                                                                                                                                         
   Coronary angiography                       144 (15.8)               159 (17.5)                                                 0.86 (0.69--1.09)    347 (29.9)   343 (29.5)   1.06 (0.91--1.22)   0.171
   Coronary revascularization                 53 (5.8)                 45 (4.9)                                                   1.15 (0.77--1.72)    226 (19.4)   222 (19.1)   1.05 (0.87--1.27)   0.652

Hazard ratios (HRs) were determined with Cox regression models adjusted for centre and minimization variables (age, body mass index, diabetes mellitus, prior coronary heart disease, and atrial fibrillation).

*P*-value for the interaction between sex and allocated treatment.

Discussion
==========

We have undertaken an analysis by sex of the main findings in the SCOT-HEART trial. Compared with men, women had differences in the typicality of their anginal symptoms, a higher likelihood of having normal coronary arteries, and more frequent diagnostic and therapeutic changes with CTCA-guided management. In particular, CTCA modified apparent over-diagnosis and treatment of women who had been incorrectly diagnosed with CHD and angina due to CHD. Both women and men appear to benefit equally from the addition of CTCA to standard care with no evidence of an interaction between sex and health outcomes identified.

In line with prior reports,[@ehz903-B17] women reported less typical anginal symptoms making clinical assessment more challenging. This diagnostic uncertainty, and lower prevalence of obstructive CHD, led to an over-diagnosis of CHD and angina. Exercise electrocardiography testing has limited sensitivity and specificity for the presence of coronary artery disease, especially in women[@ehz903-B17] which may have contributed to misdiagnosis. Indeed, women were more likely to have downstream non-invasive stress testing cancelled, and antianginal therapies reduced following reclassification by CTCA. On the other hand, ischaemia and no obstructive coronary artery disease (INOCA) caused by small vessel disease more commonly affects women.[@ehz903-B20] We suggest that CTCA-guided diagnosis and management is helpful in women for the diagnosis of angina due to CHD, but less so for INOCA. These findings extend the sex subanalysis of the CRESCENT (Calcium Imaging and Selective CT Angiography in Comparison to Functional Testing for Suspected Coronary Artery Disease) trial.[@ehz903-B21]

When compared with exercise electrocardiography testing, CTCA-guided therapy impacted on false-positive classifications without affecting false-negative classifications in women. This is in contrast to data published from the PROspective Multicentre Imaging Study for Evaluation of chest pain (PROMISE) trial, where statin therapy was lower in women than in men and women were less likely to be referred for coronary angiography[@ehz903-B19]. In PROMISE, 88% of participants had chest pain (72%) or an anginal equivalent (16%), whilst 10% had typical angina compared with SCOT-HEART where 100% had chest pain, 35% had typical angina and 9% had known CHD. The standard of care was exercise electrocardiography and the results of a trial involving different functional tests as standard of care might be different.

In our study, patients were recruited from cardiology clinics rather than general outpatient clinics. In SCOT-HEART, clinicians were free to request other non-invasive stress imaging at their discretion and indeed 10% of additional testing was requested, mostly radionuclide scintigraphy. In contrast, in the functional testing arm of PROMISE, radionuclide scintigraphy predominated (67%) with stress echocardiography and electrocardiography accounting for the remainder. We found that normal coronary arteries were two-fold more common in women whereas obstructive CHD was three-fold more common in men, similar to Pagidipati *et al*.[@ehz903-B19] This has important therapeutic implications for coronary revascularization rates and use of medical therapy across genders.[@ehz903-B10] Symptoms and quality of life improve when CTCA-guided management discloses normal coronary arteries[@ehz903-B22] and this favourable outcome associates with female sex. Typical anginal symptoms and obstructive CHD were less common in women, reflecting aetiological differences, and manifest by lower rates of coronary revascularization.[@ehz903-B17]^,^[@ehz903-B18] These findings extend those of PROMISE.[@ehz903-B23]

Women are more likely to experience angina due to small vessel disease,[@ehz903-B20] whereas obstructive CHD is more common in men. The CorMicA trial recently provided evidence that in patients with angina and no obstructive CHD, stratified medicine including adjunctive tests of small vessel function leads to improvements in angina and quality of life.[@ehz903-B20] The prevalence and clinical significance of small vessel disease in patients with chest pain and normal coronary arteries or non-obstructive CHD is being prospectively assessed in in the Coronary Microvascular Function and CT Coronary Angiography (CorCTCA) trial.[@ehz903-B24]

There are sex differences in prognosis following a diagnosis of stable angina, which is notably worse in younger women than in men.[@ehz903-B17] These differences may be explained by under-use of relevant tests and treatments.[@ehz903-B17] In our study, women had lower crude rates of adverse cardiovascular events when compared with men, and a lower rate of MI in both treatment arms. The magnitude and direction of the benefits of CTCA on fatal and non-fatal MI were similar between the sexes. There were no differences in the longer-term in coronary angiography and revascularization rates between groups for both women and men. There was a small numerically higher rate of non-cardiac death and stroke events in women in the CT group vs. the standard care group. The number of events was very low and difficult to interpret.

The interaction tests for sex, treatment group allocation, and health outcomes were not statistically significant (i.e. the null hypothesis was not rejected). Thus, the benefits of CTCA-guided management on health outcomes appear to be similar in women and men. This finding contrasts with the PROMISE[@ehz903-B25] where women appeared to gain more prognostic benefit than men from a CTCA-guided strategy. A gender-specific *post hoc* analysis from DISCHARGE (Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease, ClinicalTrials.gov identifier: NCT02400229)[@ehz903-B26] would extend whether women benefit from CTCA-guided strategy vs. invasive coronary angiography in the investigation of CHD.

Limitations
-----------

There are a number of limitations associated with this study. First, this was a *post hoc* analysis of an open-label trial and gender was not randomized. Second, this study was not designed or powered for this secondary analysis, and our findings are exploratory. Third, the small numbers of changes in the standard care arm resulted in a large variability in the relative changes that it was not possible to draw any firm conclusions from the logistic regression analyses. However, absolute differences allow for different proportions of changes in the diagnosis and establishes the gender differences we report. Finally, information on microvascular dysfunction as an alternative cause of angina was not available. Further studies are on-going.[@ehz903-B24]

Conclusions
===========

Women are less likely to have typical symptoms or obstructive CHD but are more likely to be over-diagnosed. CTCA is useful in reducing over-diagnosis and medication in women and identifies unrecognized CHD equally in both sexes with similar prognostic benefits. More research is needed to determine the causes of, and treatments for, angina in women and men with angiographically normal coronary arteries.
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======================
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